Form 8-K BIOCRYST PHARMACEUTICALS For: Aug 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies
August 5, 2024 4:01 PM EDTJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $11.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Focus heading into 2Q was on Orladyo sales, and BCRX delivered another commercial surprise (stock +5.5%) and increased guidance due to... More
